Please use this identifier to cite or link to this item:
|Research center of Embrapa/Collection:||Embrapa Gado de Leite - Artigo em periódico indexado (ALICE)|
|Type of Material:||Artigo em periódico indexado (ALICE)|
REIS, D. R. de L.
MACHADO, M. A.
COELHO, C. M.
|Additional Information:||Mayna Gomide, UFJF; Fernanda Lemos, UFMG; DANIELE RIBEIRO DE LIMA REIS FAZA, CNPGL; Gustavo José, UnB; Miriam Lopes, UFMG; MARCO ANTONIO MACHADO, CNPGL; Tânia Alves, Fundação Oswaldo Cruz; Cíntia Marques Coelho, UFJF ; UnB.|
|Title:||Identification of dysregulated microRNA expression and their potential role in the antiproliferative effect of the essential oils from four different Lippia species against the CT26.WT colon tumor cell line.|
|Publisher:||Revista Brasileira de Farmacognosia, v. 26, n. 5, p. 627-633, 2016.|
Lippia essential oil
Cell cycle phases.
|Description:||Abstract In spite of advances in colorectal cancer treatments, approximately 1.4 million new global cases are estimated for 2015. In this sense, Brazilian plant diversity offers a multiplicity of essential oils as prospective novel anticancer compounds. This study aimed to evaluate the antiproliferative effect of the essential oils from four Lippia species in CT26.WT colon tumor cells, as a measurement of cell cycle phase distribution and microRNA expression. CT26.WT showed cell cycle arrest at G2/M phase after treatment with 100 g/ml of Lippia alba (Mill.) N.E.Br. ex Britton & P. Wilson, Lippia sidoides Cham., and Lippia lacunosa Mart. & Schauer, Verbenaceae, essential oils and, at the same concentration, Lippia rotundifolia Cham. essential oil caused an augment of G0/G1 phase. The miRNA expression profiling shows change of expression in key oncogenic miRNAs genes after treatment. Our findings suggest growth inhibition mechanisms for all four essential oils on CT26.WT cells involving direct or indirect interference on cell cycle arrest and/or oncogenic miRNAs expression.|
|Appears in Collections:||Artigo em periódico indexado (CNPGL)|
Files in This Item:
|Cnpgl2016BrazJPharmacIdentification.pdf||1,1 MB||Adobe PDF|